| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +2,068,965 | 100% | $1.45 | +$2,999,999 |
| Sells | 0 | ||||
| Net | +1 | +2,068,965 | 100% | +$2,999,999 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10%+ Owner | $18,877,499 | +$2,999,999 | +19% | 21 Nov 2025 |
| Roberto Bellini | Director | $2,000,200 | 30 Jun 2025 | ||
| Christopher Cabell | President & Head of R&D | $1,353,128 | 21 Feb 2026 | ||
| Vincent Aurentz | Director | $1,021,192 | 21 Feb 2026 | ||
| Amit Munshi | Director | $806,352 | 21 Feb 2026 | ||
| Arvind Kush | Director | $198,650 | 30 Jun 2025 | ||
| Joseph Frattaroli | Cheif Financial Officer | $38,473 | 01 Mar 2023 | ||
| David McIntyre | Chief Financial Officer | $14,090 | 05 Jan 2026 | ||
| Milton H. Werner | President and CEO, Director | 21 Jan 2025 | |||
| Gisele Dion | Director | 16 Jul 2024 | |||
| Garth Lees-Rolfe | Chief Financial Officer | 21 Jan 2025 | |||
| Iwicki Mark T. | Chief Executive Officer, Director | 05 Jan 2026 | |||
| David Canner | Director | 30 Jun 2025 | |||
| Roy Lester Freeman | Director | 14 Feb 2025 | |||
| Dennis N. Berman | Director | 30 Jun 2025 | |||
| Elizabeth G. O'Farrell | Director | 24 Jun 2022 | |||
| Paul C. Grint | Director | 16 Jul 2024 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Vincent Aurentz | IKT | Common Stock | Disposed to Issuer | -33.3% | -255,299 | 510,596 | 21 Feb 2026 | Direct | ||
| Christopher Cabell | IKT | Common Stock | Disposed to Issuer | -33.3% | -338,282 | 676,564 | 21 Feb 2026 | Direct | ||
| Amit Munshi | IKT | Common Stock | Disposed to Issuer | -33.3% | -19,089 | 38,176 | 21 Feb 2026 | Direct | ||
| Iwicki Mark T. | IKT | Stock Option (Right to Buy) | Award | 4,982,706 | 4,982,706 | 05 Jan 2026 | Direct | |||
| Christopher Cabell | IKT | Stock Option (Right to Buy) | Award | 900,117 | 900,117 | 05 Jan 2026 | Direct | |||
| David McIntyre | IKT | Stock Option (Right to Buy) | Award | 986,319 | 986,319 | 05 Jan 2026 | Direct | |||
| Sands Capital Life Sciences Pulse Fund II, L.P. | IKT | Common Stock | Purchase | 18.9% | $2,999,999 | $1.45 | 2,068,965 | 13,018,965 | 21 Nov 2025 | Direct |
| Vincent Aurentz | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| David Canner | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| Amit Munshi | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| Arvind Kush | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| Dennis N. Berman | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| Roberto Bellini | IKT | Stock Option (Right to Buy) | Award | 108,176 | 108,176 | 30 Jun 2025 | Direct | |||
| David McIntyre | IKT | Stock Option (Right to Buy) | Award | 1,775,539 | 1,775,539 | 14 Apr 2025 | Direct |